asa guidelines for glp-1 Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement ASA Advises No Longer Holding
Description
Glucagon-like peptide-1: a key regulator of innate immune function with clinical efficacy in a range of inflammatory diseases
Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study
Liraglutide has been proven to ameliorate glycemic management, facilitate weight reduction, and lessen cardiovascular risk in individuals with T2D
It's frustrating to keep seeing "solutions" feed the robber barons
Yes, insomnia can be one of the side effects due to its stimulant component
Widespread use (75%) of GLP-1 RAs in the total population with type 2 diabetes was projected to prevent 16,455 MIs, 20,409 strokes, 37,100 HF hospitalisations and 39,917 deaths, but increase the number of ESKD events by 170
